Comparative Pharmacology
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus LEROCHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus LEROCHOL.
COLESEVELAM HYDROCHLORIDE vs LEROCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
None Documented
None Documented
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Category A/B
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant